Pulmonx Corp
NASDAQ:LUNG
Pulmonx Corp
NASDAQ:LUNG
Price:
9.53 USD
2.69%
Market Closed
Updated:
May 8, 2024
Pulmonx Corp
Cost of Revenue
|
Pulmonx Corp
Cost of Revenue Peer Comparison
Comparables:
COO
XRAY
ALGN
LNTH
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Pulmonx Corp
NASDAQ:LUNG
|
Cost of Revenue
-$17.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Cooper Companies Inc
NYSE:COO
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Cost of Revenue
-$1.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cost of Revenue
-$1.2B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-22%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cost of Revenue
-$491.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-9%
|
See Also
What is Pulmonx Corp's Cost of Revenue?
Cost of Revenue
-17.9m
USD
-17.9m
USD
Based on the financial report for Dec 31, 2023, Pulmonx Corp's Cost of Revenue amounts to -17.9m USD.
What is Pulmonx Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-18%
-18%
Over the last year, the Cost of Revenue growth was -30%. The average annual Cost of Revenue growth rates for Pulmonx Corp have been -16% over the past three years , -18% over the past five years .
You don't have any saved screeners yet
